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Bioluminescent resonance energy transfer (BRET
2) is a recently developed technology for the measurement
of protein-protein interactions in a live, cell-based system. BRET
2 is characterized by the efficient transfer of
excited energy between a bioluminescent donor molecule (Renilla luciferase) and a fluorescent acceptor
molecule (a mutant of Green Fluorescent Protein (GFP
2)).The BRET
2 assay offers advantages over fluorescence
resonance energy transfer (FRET) because it does not require an external light source thereby eliminating
problems of photobleaching and autoflourescence.The absence of contamination by light results in low
background that permits detection of very small changes in the BRET
2 signal. BRET
2 is dependent on the
orientation and distance between two fusion proteins and therefore requires extensive preliminary
standardization experiments to conclude a positive BRET
2 signal independent of variations in protein titrations
and arrangement in tertiary structures. Estrogen receptor (ER) signaling is modulated by steroid receptor
coactivator 1 (SRC-1).To establish BRET
2 in a ligand inducible system we used SRC-1 as the donor moiety
and ER as the acceptor moiety. Expression and functionality of the fusion proteins were assessed by transient
transfection in HEK-293 cells followed by Western blot analysis and measurement of ER-dependent reporter
gene activity.These preliminary determinations are required prior to measuring nuclear receptor protein-protein
interactions by BRET
2.This article describes in detail the BRET
2 methodology for measuring interaction
between full-length ER and coregulator proteins in real-time, in an in vivo environment.
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Introduction
The effects of 17β-estradiol (E2) are mediated through
binding to the estrogen receptor α (ERα) and estrogen
receptor β (ERβ) nuclear receptor transcription factors.
Upon ligand binding, the receptor dimerizes and recruits
coregulator proteins.The receptor-coregulator complex
binds to specific DNA sequences within the promoter
regions of ER-regulated genes to regulate gene
transcription [Edwards, 2000]. Other ligands elicit different
effects on receptor dimerization, coregulator recruitment
and DNA binding.
The importance of ERα in human physiology and breast
cancer has been clearly demonstrated. However, the role
of ERβ in breast cancer has only recently become more
evident. For example, the ERα/ERβ ratio may be altered
during carcinogenesis such that ERα expression
proportionally increases as cells progress to malignancy
[Clarke, 2003; Gustafsson and Warner, 2000].
Co-expression of ERα and ERβ and treatment with
tamoxifen increases the antagonistic effect in an ERβ
dose-dependent manner, suggesting that ERβ is a
negative regulator of ERα action [Gustafsson and Warner,
2000; Pettersson et al., 2000]. ERα and ERβ may bind
as hetero- or homo-dimers at ERE-containing promoters
[Chen et al., 1999; Ogawa et al., 1998;Tamrazi et al.,
2002;Tremblay et al., 1999].The preferential dimerization
between ERs may be key to understanding the
mechanisms regulating either tamoxifen agonist or
antagonist activity.
Most studies that examine nuclear receptor interactions
have employed artificial reporter gene assays and
co-immunoprecipitation with inherent limitations. Studies
on truncated estrogen receptor and/or coregulator
protein-protein interactions has been shown by several
in vitro mechanisms [Chen et al., 1999; Cowley et al.,
1997; Resnick et al., 2000;Valentine et al., 2000] as well
as in vivo assays using fluorescently labeled fusion
proteins such as fluorescence resonance energy transfer
(FRET) and fluorescence recovery after photobleaching
(FRAP) [Bai and Giguere, 2003; Smith et al., 1997;
Tamrazi et al., 2002]. A major challenge to understanding
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is the development of robust methods that; 1) accurately
measure protein-protein interactions in real time in live
cells; 2) exhibit specificity and low background; 3) can
identify effects of posttranslational modifications on
interactions.The application of BRET
2 addresses these
critical requirements.
BRET
2 is characterized by the efficient transfer of excited
energy between a bioluminescent donor molecule (Renilla
luciferase) and a fluorescent acceptor molecule (a mutant
of Green Fluorescent Protein).The BRET
2 assay has
advantages over FRET analysis because it does not
require an external light source, thereby eliminating the
problems of photobleaching and autoflourescence.The
absence of contamination by light results in a low
background that allows detection of very small changes
in the BRET
2 signal. BRET
2 is dependent on the
orientation and distance between two fusion proteins and
therefore requires preliminary standardization experiments
to conclude a positive BRET
2 signal, independent of
variations in protein titrations and arrangement in tertiary
structures.
Resonance energy transfer has become an invaluable
mechanism for the quantitative analysis of the transient
protein-protein interactions of hormone receptors. An
excellent review by Eidne et al. [Eidne et al., 2002]
describes application of the various methods of resonance
energy transfer to study dynamic hormone receptor
interactions within living cells.The predominant use of
BRET
2 technology to date has been to measure
membrane receptor interactions, including quantitative
analysis of hetero- and homo-dimerization and
subsequent signaling pathways of G-protein coupled
receptors [Berthouze et al., 2005; Goin and Nathanson,
2006; Harikumar et al., 2006; Huttenrauch et al., 2005;
Roy et al., 2006; Urizar et al., 2005], as well as confirming
interactions between growth factor receptors such as
IGF-1, TGF-βRII, and FGF with novel proteins [Blanquart
et al., 2005; Bottcher et al., 2004; Scaffidi et al., 2004].
To date, there are few published articles utilizing BRET
technology in nuclear receptor interactions. Utilizing
BRET
2, Garside at al. found that the glucocorticoid
receptor (GR) antagonist RU486 efficiently recruited the
nuclear corepressor NCoR to the GR, whereas
dexamethasone recruited SRC-1 [Garside et al., 2004].
More recently, Michelini et al. were the first to
demonstrate that BRET
2 can evaluate estrogen receptor
homodimerization [Michelini et al., 2004].
In this study we have extensively explored BRET
2
technology to define its use and limitations as a novel
approach to study steroid receptor protein-protein
interactions.
Reagents and instruments
Plasmid construction
The human pGFP
2-C, pGFP
2-N, pRluc(h)-C, and
pRluc(h)-N terminal expression vectors were purchased
from Perkin-Elmer Life Sciences.The GFP
2-N-ERα,
Rluc-N-SRC-1, and Rluc-C-SRC-1 fusion proteins were
constructed by amplifying the estrogen receptor and
SRC-1 fragments from the pCR3.1 vector by PCR and
digesting the KpnI and ApaI sites of both the PCR
products and the expression vectors.The GFP
2-C-ERα
fusion protein was constructed by amplifying the estrogen
receptor by PCR and digesting the BamHI and BspEI
sites of the insert as well as the expression vector. All
constructs were verified by direct DNA sequencing.
Western blotting
HEK-293 cells (ATCC) were cultured and maintained in
DMEM supplemented with 10% FBS, l-glutamine, and
antibiotics at 37°C, 95% O2, and 5% CO2. Cells (3x10
6)
were seeded in 10-cm dishes and transfected with 10µg
each of the above expression vectors using Lipofectamine
2000 transfection reagent (Invitrogen). 24 hours
post-transfection, cells were rinsed with cold PBS,
scraped from the plates and the cell pellet was lysed in
400μl of lysis buffer containing 50mM Tris-HCl (pH 7.5),
420mM NaCl, 1% NP-40, and supplemented with a
protease inhibitor cocktail (Sigma).The cell lysate was
centrifuged at 15,000 x g at 4°C for 20 minutes.The
protein concentration in the supernatant was determined
and 50μg of protein lysate was boiled in Laemmli loading
buffer and subjected to a 10% SDS-PAGE for Western
blotting with antibodies to ERα (VPE-614, Vector
Laboratories, Burlingame, CA), GFP (SC9996, Santa
Cruz Biotechnology, Santa Cruz, CA) or Rluc (MAB4400,
Chemicon, Temecula, CA).
Co-immunoprecipitations
HEK-293 cells were cultured and transfected as described
above. Cells (3x10
6) were transfected with 10μg of
Rluc-C-SRC-1 and 10μg GFP
2-C-ERα or vector. 48 hours
post-transfection, cells were rinsed in cold PBS, scraped
from the dishes and the cell pellet was lysed in 400μl of
hypotonic lysis buffer (20mM HEPES pH 7.5, 10%
glycerol, 1mM PMSF) using five strokes of a dounce
homogenizer.The lysate was centrifuged at 1,000 x g at
4°C for 20 minutes to pellet the nuclei.The cytosolic
supernatant was removed and set aside at 4°C.The
volume of the packed nuclei (Packed Cell Volume, or
PCV) was determined and low-salt NP-40 lysis buffer
(20mM HEPES pH7.5, 150mM NaCl, 1% NP-40, 50mM
Tris-HCl pH 7.5, 1mM PMSF) was added at twice the
PCV.The nuclear pellet was vortexed at 5 minute
intervals for 30 minutes at 4°C, then centrifuged at 15,000
x g for 10 minutes at 4°C.The nuclear extract was
combined with the cytosolic extract and the protein
concentration was determined. Separating the cytosolic
and nuclear extracts in this manner was found to preserve
the protein-protein interactions and increase the yield.
500μg of combined cell lysate was pre-cleared by
incubation with Protein A agarose beads for 30 minutes
at 4°C.The pre-cleared supernatant was then incubated
with SRC-1 antibody (0.5µg/100µg lysate; M-341, Santa
Cruz) rotating overnight at 4°C. 20µl of Protein A agarose
beads were added and the solution and incubated for 1
hour at 4°C while rotating.The resulting protein
A/immunocomplex was then centrifuged at 15,000 x g for
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and repeated 3x.The beads were boiled in Laemmli
loading buffer for 10 minutes and followed by
electrophoresis by 10% SDS-PAGE.
Luciferase assays
HeLa cells were cultured in phenol-red free DMEM with
5% fetal bovine serum and plated in 6-well dishes at a
confluency of 2x10
5 cells/well.The medium was replaced
with medium containing 2% dextran-coated
charcoal-stripped serum and the cells were incubated for
48 hours. Cells were then transfected with 500ng of
EREe1b-luciferase reporter using Fugene6 transfection
reagent. 24 hours post-transfection, cells were incubated
with vehicle or 10
-8 M estradiol for 24 hours.The cells
were lysed with luciferase lysis buffer and centrifuged at
20,000 x g at room temperature for 5 min. to remove
cellular debris.The supernatant was used for a standard
luciferase assay using a luminometer and luciferase assay
values were normalized to protein measured by Bradford
assay.
Bioluminescence Resonance Energy Transfer
(BRET
2)
HEK-293 cells were plated in 6-well plates (200,000
cells/well) and incubated in medium containing 5%
charcoal-stripped serum overnight. Cells were transfected
with varying amounts of the BRET
2 expression vectors
using Lipofectamine 2000 (Invitrogen) transfection
reagent. 48 hours post-transfection, the cells were
harvested and washed 2x in BRET Buffer (PBS plus
2μg/ml aprotinin). 50,000 cells in 40μl buffer were
incubated with vehicle or 10
-8M estradiol for 30 minutes
at room temperature in 96-well white Optiplates
(PerkinElmer). Following addition of 5μM DeepBlueC
substrate, luminescence and fluorescence emissions
were measured immediately on the Packard Fusion
instrument at 410nm and 515nm, respectively. An
extensively detailed protocol for BRET
2 follows.
Methods
Since BRET
2 requires transfection of fusion proteins,
receptor negative cell lines that exhibit high transfection
efficiency should be used. Standardization experiments
must be performed before assaying fusion proteins of
interest.We suggest using known interacting proteins
and their respective agonists as a positive control when
first applying BRET
2 methodology.We found HEK-293
cells, in which most reported data with BRET
2 has been
documented, exhibited the highest transfection efficiency
and protein expression for the very large coactivator
fusion proteins used in this study. Consequently, HEK-293
cells yielded the most robust BRET
2 signal when
assessing ERα interactions.To assess functionality of
the ERα and SRC-1 fusion proteins, HeLa cells were
used. Although transfection efficiency, fusion protein
expression and consequently BRET
2 signal was reduced
in HeLa compared to HEK-293 cells, HeLa cells are well
characterized for response to estradiol in reporter gene
assays and recruitment of coregulators and are therefore
deemed most appropriate to confirm the functionality of
the fusion proteins in comparison to wild-type proteins.
The protocol detailed below is adapted from the
PerkinElmer technical data sheet for catalog number
6310556, Appendix A (www.perkinelmer.com).
Preliminary experiments
1. Create a minimum of four fusion protein vectors for
each protein to test whether differences in protein folding
and post-translational modifications may contribute to the
interaction.The orientation of the BRET
2 tag can also
effect protein expression and function. GFP
2 and Rluc
fusion construct combinations are shown in
Supplementary File 1.
2.Verify the functionality and expression of all
combinations of fusion proteins. Expression can be
assayed by immunoblot, and the functionality of each
nuclear receptor fusion protein can be confirmed with a
standard reporter gene assay in which the reporter
contains the hormone responsive element for the nuclear
receptor. Quantitative expression of each fusion protein
can also be tested individually by the Fusion instrument.
Testing the expression of each bioluminescent/fluorescent
fusion protein signal separately will provide the user with
the maximum level of fluorescence/luminescence output
without resonance energy transfer.
- For the GFP
2 signal: In a 96-well black Optiplate, aliquot
50,000 transfected cells/well (25μl) and add 175μl BRET
2
buffer. Read on the Fusion instrument (Fluorescence
mode). (PMT:1000 volts, Gain:1, read time 0.5 sec,
excitation 425/20, emission 515/30).
- For the Rluc signal: In a 96-well white Optiplate, aliquot
50,000 cells/well (25μl) and add 150μl BRET
2 buffer. Add
50μl of 20μM coelentrazine h (5μM final). Incubate
covered with foil 18 minutes. Read on the Fusion
instrument (Luminescence mode). (PMT:900, Gain:1,
read time 1 sec, emission 410).
BRET
2 assay
The optimal amount of each fusion protein construct used
in co-transfection experiments depends on factors such
as the affinity of the two interacting domains and the
levels at which each construct is expressed. For this
reason, a simple 1:1 ratio of DNA may not yield the best
results.Therefore, a transfection matrix experiment must
be performed with various ratios of each construct and
used for BRET
2 measurements. Supplementary File 1
shows an example of a BRET
2 transfection matrix.
1.Transfect HEK-293 cells in 100mm dishes with
combinations of DNA listed above using Lipofectamine
2000 according to the manufacturer’s instructions. Use
GFP
2 vector (without insert) when transfecting the
Rluc-Protein B to keep the DNA concentration constant
(Conditions 2, 7, and 12).
2. BRET
2 assays can be performed 24-72 hours
post-transfection depending on protein turnover and cell
doubling-time. At the time of the assay, wash cells in
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2 and nuclear receptorsFigure 1.  Expression of the GFP
2-C and -N terminal estrogen receptor and Rluc-C-SRC-1 fusion proteins assessed by Western blot analysis
HeLa cells were plated in 10-cm dishes and transfected with 5µg each of the above expression vectors. 100µg of total cell extract was prepared for
8% SDS-PAGE and Western blotting with antibody to hERα (A and B), or Rluc (C).Transfection efficiency of the GFP
2-Rluc positive control vector at
24 hours post-transfection in phase contrast (E) or the overlay of the phase contrast on the GFP filter (F) on a fluorescent microscope.
BRET
2 buffer (Dulbecco’s Phosphate Buffered Saline
(D-PBS) containing CaCl2 (0.1g/l), MgCl2 (0.1g/l), and
D-Glucose (1g/l) supplemented with Aprotinin (2μg/ml))
twice, and harvest in BRET
2 buffer.
3. Count the cells and resuspend 1x10
6/ml in BRET
2
buffer. Aliquot 50μl (50,000) cells in triplicate into a 96-well
white Optiplate.This constitutes the non-treated cells.
Aliquot another 50μl cells in triplicate for each ligand.
4. Add ligand (diluted in BRET
2 buffer) or buffer alone to
each well. Incubate at room temperature for 30 minutes.
For example, add 6μl of a 1μM dilution of Estradiol for a
final concentration of 10nM (56μl total).
5. Start BRET
2 reaction by adding 14μl of 25μM (5μM
final) DeepBlueC substrate one column at a time (70μl
total volume). Read each column immediately on the
Fusion instrument before addition of substrate to the next
column.
6. Immediately following addition of DeepBlueC, read the
plate on a Fusion microplate analyzer with the following
settings: one second per well, PMT: 1100 volts and gain:
100, using the following 410/515 nm filter pairs: a) Rluc
emission: 410 nm bandpass 80 nm; b) GFP
2 emission:
515 nm bandpass 30 nm.
BRET
2 can be further optimized by altering the number
of cells assayed. After determining the greatest difference
in signal to background from the transfection matrix (see
data analysis), titrate the number of cells (50,000 to
200,000) from that particular ratio.The number of cells
per well depends on protein expression levels and
transfection efficiencies (i.e., the lower the protein
expression, the higher the number of cells required). For
each co-transfection, it is also necessary to assay
Rluc-Protein B co-transfected with the empty GFP
2 vector,
and untransfected cells alone for calculation purposes
(see below). For example, if Condition 3 (a co-transfection
of both GFP
2-Protein A and Rluc-Protein B) yield the
highest BRET
2 signal, one must simultaneously assay
the same amount of Rluc-Protein B expressed with the
empty GFP
2 vector (Condition 2), as well as assay
untransfected cells (Condition 1).
7. Resuspend cells in varying concentrations (1x10
6/ml
to 4x10
6/ml) and aliquot 50μl of cells in triplicate per
concentration. An example of a 96-well Optiplate is shown
under “Cell number titration” in Supplementary File 1.
8. Follow with steps 6-8 for BRET
2 analysis.
Data analysis
The average counts obtained between the triplicate wells
with non-transfected cells (treated or untreated with
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cells in each well (with or without ligand, respectively) to
obtain the corrected counts at both wavelengths. Using
the corrected counts, the BRET
2 signal is then determined
as the ratio between GFP
2 emission (515 nm) and Rluc
emission (410 nm).This is illustrated in Calculation #1,
Supplementary File 1. (When subtraction of the
background counts yields negative values, a BRET
2 ratio
of zero is assigned.)
There are two calculations to analyze the BRET
2 ratio
(Supplementary File 1). Both are independent and derived
from the basic dogmatic principle of resonance energy
transfer; GFP
2 emission/Rluc emission. Both are correct
and either can be used depending on presentation of
data. Calculation #1 (Supplementary File 1) is best for
presenting ligand-dependent versus ligand-independent
interactions because it simply subtracts raw background
emission from itself. In the assay above, subtract the
fluorescence signal of Condition 1 (non-transfected) by
the fluorescence signal of Condition 3 (GFP
2-Protein A
and Rluc-Protein B co-transfection) divided by the
luminescence signal of Condition 1 subtracted by the
luminescence signal of Condition 3.
Calculation #2 (Supplementary File 1) is the corrected
BRET
2 ratio (Calculation #1) and subtracts the correction
factor.The correction factor is the corrected
fluorescent/luminescent signal for the Rluc-Protein B
expressed with the empty GFP
2 vector. Instead of
visualizing basal interactions as with Calculation #1, it
incorporates possible false positive resonance energy
transfer signals due to forced interactions between
over-expressed Rluc or GFP
2 fusion proteins.This
calculation is best for comparing time-course or multiple
ligands in one graph. In the assay described above, use
Calculation #1 to calculate the corrected BRET
2 ratio of
both the Rluc-Protein B expressed with the empty GFP
2
vector (Condition 2, or Cf), and the GFP
2-Protein
A:Rluc-Protein B co-transfection (Condition 3).Then
subtract corrected Condition 2 from the corrected
Condition 3.
Results
We have used the well characterized examples of
estradiol-dependent dimerization of ERα and
estradiol-dependent recruitment of the coactivator SRC-1
to demonstrate application of BRET
2.The following data
obtained using BRET
2 technology is consistent with
previously reported data using other methodologies and
establishes BRET
2 as a viable methodology to measure
well characterized estrogen receptor functions.
Expression of GFP
2-C and -N terminal estrogen
receptor and Rluc-C-SRC-1 fusion proteins
Figure 1A-C shows the expression of the GFP
2-C and -N
terminal estrogen receptor and Rluc-C-SRC-1 fusion
proteins by Western analysis in the ER negative human
cervical carcinoma cell line, HeLa. Figure 1D-E
demonstrates the transfection efficiency of the GFP
2-Rluc
positive control vector at 24 hours post-transfection in
HEK-293 cells.Wild-type ER is 66kD molecular weight.
Based on primary sequence, the predicted molecular
weights of the GFP
2-ERα, Rluc-ERα and Rluc-SRC-1
constructs are 93kD, 100kD, and 195kD, respectively
and Western blot signals corresponding to these sizes
are detected (Figure 1). Other bands evident on the
Western blots are the results of either non-specific
antibody signal (Figure 1C, all lanes) and/or partial protein
degradation during lysis (Figure 1A).
Functional analysis of N- and C-terminal fusion
proteins of ERα and SRC-1
Figure 2 demonstrates the functionality of the ERα and
SRC-1 fusion proteins by transient co-transfection with
the ERE2e1b-luciferase reporter plasmid in ER-negative
HeLa cells followed by standard luciferase assays. All
combinations of N- and C- terminal SRC-1 fusion proteins
potentiated GFP
2-ERα activation of the reporter (Figure
2 A, B, D) with the exception of the combination of
GFP
2-N-ERα and Rluc-C-SRC-1 (Figure 2C). One
possible reason for the absence of coactivation by this
combination may be interference of the fluorescent tags
with receptor-coactivator interaction. Direct comparison
between the fusion proteins with wild type ERα and
SRC-1 confirmed that the fusion proteins had comparable
activity to wild type proteins in estradiol activation and
coactivation of the ERE2e1b-luciferase reporter (Figure
2E-F). It is important to note that expression of Rluc fusion
proteins may contribute to the luciferase reporter gene
assay. Luciferase assays may also be used to measure
expression of the fusion protein in cells. Although
expression of Rluc-C-SRC-1 did not appear to contribute
significantly to the luciferase assays in Figure 2, the
investigator must recognize this caveat when luciferase
reporter gene assays are used to measure the
functionality of Rluc fusion proteins.
ERα homodimers demonstrated by the BRET
2
assay
To first determine the dose of estradiol required to
stimulate homodimerization as assessed by BRET
2 in
HEK-293 cells, an agonist dose response curve was
generated. Estradiol stimulated ER homodimerization in
a dose dependent manner (data not shown).We
assessed estradiol-dependent homodimerization by
BRET
2 using different combinations of GFP
2 and Rluc,
C- and N- terminal ERα fusions. By titration of GFP
2-ERα
and Rluc-ERα expression vectors it was determined that
transfection of 10μg of both the GFP
2-ERα and the
Rluc-ERα fusion vectors resulted in the maximum
estradiol-dependent dimerization as assessed by BRET
2.
All combinations of C- and N-terminal ERα fusion proteins
exhibited homodimerization in response to estradiol
(Figure 3A).The maximum observed BRET
2 ratio
occurred when using the GFP
2-N-ERα, and Rluc-C-ERα
fusion proteins (Figure 3A). In Figure 3B, the dashed line
represents background BRET
2 signal assessed from cells
co-transfected with Rluc-C-ERα and the GFP
2 vector.
This negative control accounts for any false-positive
BRET
2 signals due to protein over-expression. In addition
to estradiol induced homodimerization, we also observed
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2 and nuclear receptorsFigure 2.  Fusion of GFP
2 or Rluc to ERα and SRC-1 does not alter protein function HeLa cells were transfected with 100ng of GFP
2-C-ERα
(A and B) or GFP
2-N-ERα (C and D) expression vector with increasing amounts (100, 200, 400, 600, 800, 1000 ng) of either Rluc-C-SRC-1 (A and C)
or Rluc-N-SRC-1 (B and D) expression vector, and 500ng of ERE-luciferase reporter, and the remaining amount of DNA with a vector containing a
CMV promoter.The DNA levels were equivalent, with 1600ng of total transfected DNA.To confirm that the fusion proteins had comparable activity to
wild type proteins, cells were transfected with reporter gene and 100ng of GFP
2-C-ERα or WT-ERα to compare ERα activity (E) or with 100ng of
GFP
2-C-ERα + 500 ng of Rluc-C-SRC-1 or WT-SRC-1 to compare SRC-1 activity (F). All cells (A-F) were incubated with either vehicle or 10
-8M estradiol
for 24 hours.The cells were lysed and luciferase expression was measured by a luminometer.
ligand-independent homodimerization of ERα (Figure 3B,
bar 3). Estradiol induced GFP
2-C-ERα and Rluc-C-ERα
homodimerization within 30 minutes (data not shown)
and continued to stimulate this interaction for up to 12
hours (Figure 4A).To confirm the dimerization identified
by BRET
2, HEK-293 cells cotransfected with GFP
2-C-ERα
and Rluc C-ERα were coimmunoprecipitated with an
antibody to GFP and probed by Western blot with
antibody to Rluc (Figure 4B).
Interaction of ERα and the nuclear coactivator
SRC-1 demonstrated by the BRET
2
Figure 5 demonstrates the estradiol-dependent interaction
of ERα and SRC-1 by titration of the GFP
2-C-ERα and
Rluc-C-SRC-1 fusion proteins as assessed by BRET
2.
The maximum BRET
2 signal was approximately two-fold
compared to basal interaction and occurred at 10μg of
both GFP
2-C-ERα and Rluc-C-SRC-1.The basal BRET
2
signal is represented by the Rluc-C-SRC-1 fusion protein
expressed without the estrogen receptor (Figure 5A).
Estradiol induced interaction between GFP
2-C-ERα and
Rluc-C-SRC-1 within 1 hour and continued to stimulate
this interaction for up to 12 hours (Figure 5B).The
estradiol-dependent interaction between GFP
2-C-ERα
and Rluc-C-SRC-1 was confirmed by
co-immunopreciptation (data not shown). Interestingly,
in the absence of ligand there was a decrease in the
BRET
2 ratio over time when measuring ERα/SRC-1
interaction, but not ERα dimerization. It is possible that
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2 and nuclear receptorsFigure 3.  17β-estradiol induced homo-dimerization of the ERα as assessed by BRET
2 HEK-293 cells were transiently co-expressed with the
GFP
2-C-ERα (40µg) and Rluc-C-ERα (10µg) fusion proteins to generate a dose-response curve with estradiol treatment (data not shown).The
estradiol-induced interaction by BRET
2 occurs between all combinations of ERα fusion proteins, regardless of differences in tertiary structure. HEK-293
cells were transfected with 10µg each of a GFP
2-ERα and Rluc-ERα fusion protein and incubated with vehicle or 10
-8 M estradiol for 30 minutes (A).
Luminescence and fluorescence emissions were then read immediately following addition of DeepBlueC substrate for the BRET
2 assay.To determine
the ligand-dependent and -independent homodimerization of ERα, HEK-293 were transfected with 10µg of Rluc-C-ERα and 10µg of either GFP
2-C-ERα
or the GFP
2-C vector alone and treated for 30 minutes with 10
-8M estradiol (B).The ligand-dependent and -independent BRET
2 interaction of GFP
2-C-ERα
and Rluc-C-ERα with and without estradiol treatment is indicated by bars above the dashed line.The dashed line represents basal activity.This figure
is representative of five experiments.
Figure 4. Time course for ligand-dependent ERα homodimerization as assessed by BRET
2 HEK-293 cells were co-transfected with Rluc-C-ERα
and either GFP
2-C-ERα or the GFP
2 vector alone.The cells were incubated with vehicle (DMSO) or 10
-8M estradiol (E2).The BRET
2 assay was
performed at a time course of 1, 4, 8, and 12 hours (A).The BRET
2 signal was performed in triplicate and repeated three times. Co-immunoprecipitation
confirms estradiol-induced homodimerization between GFP
2-C-ERα and Rluc-C-ERα (B). HEK-293 cells were untransfected (Lane 1) or transfected
with 10µg each of Rluc-C-ERα and 10µg of GFP
2-C vector (Lane 3), and incubated with 10
-8M estradiol. Immunoprecipitated Protein A agarose beads
without antibody was used as a control (Lane 2).Whole cell lysate was immunoprecipitated with ERα antibody followed by Western blot for ERα.The
molecular weight of Rluc-C-ERα is 101kD.
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of ligand may be cyclical or sporadic.This possibility is
currently under investigation.
Figure 5.  Ligand-dependent interaction between GFP
2-C-ERα and
Rluc-C-SRC-1 as assessed by BRET
2 (A) HEK-293 were transfected
with 10μg of Rluc-C-SRC-1 and 10µg of either GFP
2-C-ERα or the GFP
2-C
vector alone and incubated for 30 minutes with 10
-8M estradiol.The
ligand-dependent interaction of GFP
2-C-ERα and Rluc-C-SRC-1 in the
presence of estradiol treatment is indicated by the bar above the dashed
line.The dashed line represents basal activity. (B) Time course for ligand
dependent interaction between ERα and SRC-1. HEK-293 cells were
incubated with vehicle (DMSO) or 10
-8M estradiol (E2). Figure is
representative of five experiments.
Discussion
We demonstrate the use of BRET
2 to assess in vivo
protein interactions between nuclear receptors and
coregulators in real-time.To establish BRET in a ligand
inducible system, we chose to use the nuclear coactivator
SRC-1 as the donor moiety, and the estrogen receptor
as the acceptor moiety. Functionality of these fusion
proteins was assessed by transient transfection in HeLa
cells, followed by Western blot analysis for protein
expression and reporter gene activity.Titration of ER and
SRC-1 protein levels was needed to obtain an accurate
molar ratio of the Rluc and GFP
2 fusion proteins needed
for BRET.
Published work with BRET
2 does not contain
standardization experiments that are imperative to
conclude a positive BRET
2 signal for data interpretation.
Although BRET
2 is a sensitive assay for assessing ligand
and time dependent changes in nuclear receptor
interactions in live cells, one limitation of BRET
2 is that it
is not quantitative.This is because ligand-induced
conformational changes of the receptor may place the
GFP
2 moiety too distant from the Rluc moiety for efficient
resonance energy transfer. Consequently, a large
increase in the BRET
2 ratio may not necessarily indicate
a quantitatively greater interaction between proteins than
smaller increases in the BRET
2 ratio.
The functionality of the fusion proteins must be confirmed
prior to assessing protein interactions by BRET
2. Once
the function of the fusion proteins are confirmed, titrations
of the transfected expression constructs must also be
performed to exclude background and insignificant BRET
signals. Background BRET
2 signal is defined as the
fluorescent/luminescent quantitative number measured
by the Fusion instrument for untransfected cells. An
insignificant BRET
2 signal is a signal that can occur by
overexpression of the fusion proteins. Nuclear receptor
function may also be assessed by other common
approaches such as ligand binding, DNA binding,
subcellular localization, and measuring endogenous
receptor-regulated gene expression. Coactivator
functionality is commonly assessed by their ability to
enhance the transcriptional activity of steroid receptors.
The ERα negative human embryonic kidney cell line
HEK-293 is especially amenable to BRET
2 analysis (see
description of BRET
2 at www.perkinelmer.com). Using
only the ER ligand-binding domain instead of full-length
receptor, previous reports using FRET demonstrated that
dimerization is estradiol dose-dependent [Bai and
Giguere, 2003;Tamrazi et al., 2002].We show not only
full-length estrogen receptor homodimerization, but also
ERα interaction with the coactivator SRC-1, is
dose-dependent, induced within thirty minutes, and stable
over a twelve-hour time period.
Application of BRET
2 for studying nuclear
receptor interactions
BRET
2 is an excellent method for measuring nuclear
receptor interactions with other proteins as a
consequence of specific ligand binding, receptor
mutations and posttranslational modifications in a
time-dependent manner. For example, this study, which
demonstrates and validates BRET
2 for nuclear receptor
interactions, uses full-length estrogen receptor and
estradiol dependent receptor dimerization and recruitment
of coactivator SRC-1. A simple extension of this study to
include existing or novel ligands for ER would yield time
dependent data comparing receptor homodimerization
and SRC-1 recruitment. In this manner, BRET
2 would
become especially useful in comparing activity of novel
SERMs.Through preparation of fusion constructs for ERβ
and other coregulators, information about additional
nuclear receptor interactions could be obtained. Nuclear
receptor posttranslational modifications such as
phosphorylation, acetylation, and sumoylation among
others play an important role in protein-protein interactions
[Fu et al., 2004; Rochette-Egly, 2005; Sentis et al., 2005].
Receptor posttranslational modifications in response to
subcellular localization, ligands, drugs, or peptide
hormone signaling pathways impacts nuclear
receptor-dependent gene transcription and can regulate
the relative agonist/antagonist properties of mixed ligands.
Using the example of receptor phosphorylation, BRET
2
technology can measure the precise contribution of single
and multiple receptor phosphorylation sites to
dimerization, coregulator recruitment and interactions
with other proteins through preparation of point mutations
in the receptor GFP- or Rluc-fusion proteins.
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